Re-standardisation of Total Protein Assay
October 25, 2025
The supplier of our Total Protein test has modified their calibrator to ensure traceability to the National Institute of Standards and Technology (NIST). The net effect on our Total protein results is an increase of 4% which is within clinically acceptable limits as determined by the College of American Pathologists (CAP). Pathlab will be amending our Total Protein and Globulin reference intervals…
Keep Reading →
HPV Dry Swab Tube Collection Kit
October 17, 2025
Pathlab are pleased to announce the release of the new Human Papilloma Virus (HPV) Dry Tube Collection kit from late October 2025. This new kit will replace the existing HPV buffer (wet) tube kit and has a few differences. The pink capped tube label looks slightly different with two rows of small 2D barcodes and an additional pink strip at the bottom. Please ensure that one row of the 2D barcodes…
Keep Reading →
Anti-MPO Reagent Change
October 14, 2025
The manufacturer of anti-MPO reagent (for ANCA testing) has improved the assay thus resolving problems sometimes encountered by the laboratory, which while did not affect patient results, did affect laboratory processes. This improvement has caused a one-time shift in numerical values downwards. This may be a significant shift in some patient results compared to previous ones using the old reagent…
Keep Reading →
Delay in Infectious Serology Testing
July 02, 2025
Due to an unexpected analyser failure on Monday, followed by a delay in the shipment of required parts from Sydney due to cancelled freight flights, the following tests are currently unable to be processed at Pathlab. Anti-TPO antibodies CMV serology EBV serology Hepatitis B serology Hepatitis A serology Hepatitis C antibody HIV serology Rubella IgG Syphilis screen Toxoplasma serology HIV screen…
Keep Reading →
Reporting of Referral Laboratory Name
June 16, 2025
Pathlab laboratories are audited under ISO Standard 15189:2022, which sets requirements for quality and competence. This standard, revised in 2022, adopts a risk-based approach to our quality systems. Two new clauses were introduced: 7.4.1.4 Special considerations for results - 1. When agreed with the user, the results may be reported in a simplified way. Any information listed in clauses 7.4.1.…
Keep Reading →